ERBB2 and pancreatic neoplasm: Numerous ongoing clinical studies are utilizing trastuzumab for pancreatic cancer treatment, and in a recent study, Hirokawa et al. reported that patients with HER2-positive heterotopic pancreatic cancer responded well to trastuzumab treatment [143].